Physician profile
Emad Alshami
NPI 1336168848
$98,224.62
in general payments reported to CMS, 2019-2025
29 companies · $40K in 2025
The $40K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $2,572 · 2021: $4,199 · 2022: $7,206 · 2023: $21K · 2024: $11K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $55K · Food and Beverage: $8,451 · Consulting Fee: $5,500 · Travel and Lodging: $2,785 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,940.00 |
| Food and Beverage | $8,450.76 |
| Consulting Fee | $5,500.00 |
| Travel and Lodging | $2,785.32 |
| Education | $119.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $54,272.94 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21,612.15 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $8,085.76 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Allergan, INC. | $6,979.68 | 2019-2020 | |
| Lundbeck LLC | $1,481.53 | 2019-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $998.44 | 2019-2025 | Invega Trinza, Invega Sustenna, Spravato |
| Alkermes, INC. | $917.01 | 2019-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $540.80 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $533.55 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Sunovion Pharmaceuticals INC. | $485.74 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $425.69 | 2022-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $354.17 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $254.07 | 2022-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $248.16 | 2019-2024 | Trintellix |
| Corium, LLC | $193.16 | 2022-2024 | Azstarys |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $168.64 | 2021-2024 | Loreev Xr |
| Avanir Pharmaceuticals, INC. | $113.85 | 2019-2022 | |
| Bausch Health US, LLC | $110.19 | 2019-2021 | |
| Indivior INC. | $67.00 | 2021-2022 | |
| Alpha Cognition USA, INC. | $64.30 | 2025 | Zunveyl |
| Ironshore Pharmaceuticals INC. | $63.62 | 2019-2022 | |
| Shire North American Group INC | $52.02 | 2019 | |
| Eisai INC. | $46.40 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $43.31 | 2020-2022 | |
| Noven Therapeutics, LLC | $30.28 | 2022 | |
| Tris Pharma INC | $28.73 | 2025 | Dyanavel Xr |
| Sage Therapeutics, LLC | $22.98 | 2025 | Zurzuvae |
| Masimo Corporation | $16.25 | 2024 | Set and Rainbow Set |
| Idorsia Pharmaceuticals US INC | $14.20 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emad Alshami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.